Lantheus receives Complete Response Letter for LNTH-2501
Seeking Alpha ·
The US FDA issued a Complete Response Letter to Lantheus ( LNTH ) for LNTH-2501, its PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors. The agency noted the application cannot be approved because of ongoing issues at a third-party manufacturing
DYAX Investor Sentiment
Bullish (Long) 61% · Bearish (Short) 39%
349 participants
Related News
- Why Microsoft Stock Rose Today
- Where Will XRP Be in 3 Years?
- S&P 500, Nasdaq End Week Lower As Investors Rotate Out Of Tech, AI Plays — ON, AAPL, SLS, INFQ, NKE in Focus
- Uber (UBER) Shares Skyrocket, What You Need To Know
- What If The Real Power Behind Marvell Stock Isn't Just Growth?
- Adobe (ADBE) Buys Topaz Labs As It Expands Agentic AI Partnerships